Drugs / RBI-4000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06048770 | Sep 2023 → Jul 2024 | — | Replicate Bioscience | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-09-24 | Replicate Bioscience | Results Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000 replicatebioscience.com ↗
Continuation of this Phase I trial for up to 8 months, including 5 months of additional durability data, showed that RBI-4000 elicited long-term immune responses to rabies at all dose levels and regimens tested. |
| 2025-02-07 | Replicate Bioscience | Results Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications replicatebioscience.com ↗
The Phase I study showed that a single dose of RBI-4000 elicited immune responses that attained a World Health Organization (WHO)-established immune threshold of protection against rabies across all dose levels tested, with good tolerability. |
| 2024-05-11 | Replicate Bioscience | Results Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting replicatebioscience.com ↗
Positive data from Phase 1 trial of RBI-4000 vaccine achieve WHO-established surrogate of protection across all dose cohorts |
| 2024-04-22 | Replicate Bioscience | Results Replicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting replicatebioscience.com ↗
Interim analysis of a Phase 1 trial demonstrate that all doses were well tolerated and that RBI-4000 was immunogenic at all dose levels tested, conferring protection with a single, low dose. |
| 2024-02-13 | Replicate Bioscience | Results Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology replicatebioscience.com ↗
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today shared positive results from the Phase 1 trial of RBI-4000, its srRNA-based rabies vaccine. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBI-4000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06048770 ↗ |
| Route | Intramuscular | “RBI-4000 administered at various dose levels via intramuscular injection” NCT06048770 ↗ |